RS54744B1 - Rastvorljivi funkcionalni heterodimeri mhc klase ii stabilizovani disulfidnom vezom - Google Patents
Rastvorljivi funkcionalni heterodimeri mhc klase ii stabilizovani disulfidnom vezomInfo
- Publication number
- RS54744B1 RS54744B1 RS20160323A RSP20160323A RS54744B1 RS 54744 B1 RS54744 B1 RS 54744B1 RS 20160323 A RS20160323 A RS 20160323A RS P20160323 A RSP20160323 A RS P20160323A RS 54744 B1 RS54744 B1 RS 54744B1
- Authority
- RS
- Serbia
- Prior art keywords
- mhc class
- molecule
- molecules
- class
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30572810P | 2010-02-18 | 2010-02-18 | |
| GBGB1002730.8A GB201002730D0 (en) | 2010-02-18 | 2010-02-18 | Product |
| US31657610P | 2010-03-23 | 2010-03-23 | |
| PCT/GB2011/050325 WO2011101681A2 (en) | 2010-02-18 | 2011-02-18 | Disulphide bond-stabilized functional soluble mhc class ii heterodimers |
| EP11730044.2A EP2536746B1 (en) | 2010-02-18 | 2011-02-18 | Disulphide bond-stabilized functional soluble mhc class ii heterodimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54744B1 true RS54744B1 (sr) | 2016-10-31 |
Family
ID=42113985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160323A RS54744B1 (sr) | 2010-02-18 | 2011-02-18 | Rastvorljivi funkcionalni heterodimeri mhc klase ii stabilizovani disulfidnom vezom |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8828379B2 (https=) |
| EP (1) | EP2536746B1 (https=) |
| JP (1) | JP5537675B2 (https=) |
| KR (1) | KR101647176B1 (https=) |
| CN (1) | CN102947330B (https=) |
| AU (1) | AU2011217027B2 (https=) |
| CA (1) | CA2789492C (https=) |
| CY (1) | CY1117697T1 (https=) |
| DK (1) | DK2536746T3 (https=) |
| ES (1) | ES2572388T3 (https=) |
| GB (1) | GB201002730D0 (https=) |
| HR (1) | HRP20160475T1 (https=) |
| HU (1) | HUE027952T2 (https=) |
| PL (1) | PL2536746T3 (https=) |
| RS (1) | RS54744B1 (https=) |
| RU (1) | RU2604813C2 (https=) |
| SI (1) | SI2536746T1 (https=) |
| WO (1) | WO2011101681A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| ES3011307T3 (en) | 2012-02-23 | 2025-04-07 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP4592400A3 (en) | 2012-10-17 | 2025-10-29 | 10x Genomics Sweden AB | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| JP6748061B2 (ja) * | 2014-07-09 | 2020-08-26 | ルピン・リミテッド | 二重シストロン細菌発現システム |
| US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
| US12577289B2 (en) | 2015-06-30 | 2026-03-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Surrogate co-receptors for t cells and methods of use |
| MX2018004875A (es) | 2015-10-22 | 2018-08-01 | Juno Therapeutics Gmbh | Metodos para cultivar celulas y kits y aparatos para ello. |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| US20180127481A1 (en) * | 2016-11-09 | 2018-05-10 | Uti Limited Partnership | RECOMBINANT pMHC CLASS II MOLECULES |
| JP7339160B2 (ja) | 2017-04-27 | 2023-09-05 | ジュノ セラピューティクス ゲーエムベーハー | オリゴマー粒子試薬およびその使用方法 |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| EP4345453B1 (en) * | 2018-09-28 | 2025-11-12 | 10X Genomics, Inc. | High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules |
| SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3719033A1 (en) * | 2019-04-02 | 2020-10-07 | imusyn GmbH & Co. KG | Stabilized mhc i |
| WO2021035049A1 (en) * | 2019-08-21 | 2021-02-25 | Uti Limited Partnership | Improved recombinant pmhc molecules |
| EP4028412A2 (en) * | 2019-09-13 | 2022-07-20 | The Regents of The University of California | Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications |
| US20220409732A1 (en) * | 2019-12-02 | 2022-12-29 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| DE102020109447A1 (de) | 2020-04-03 | 2021-10-07 | Jacobs University Bremen Ggmbh | Synthetisches mhc-klasse-ii-protein |
| US12534510B2 (en) | 2020-04-16 | 2026-01-27 | The Regents Of The University Of California | Peptide-receptive MHC-I complex compositions and methods |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN118813436A (zh) * | 2023-07-24 | 2024-10-22 | 佳吾益(北京)科技有限公司 | 展示单mhc等位基因功能蛋白的工程化细胞 |
| CN119220425A (zh) * | 2023-07-28 | 2024-12-31 | 佳吾益(北京)科技有限公司 | 发现mhc新抗原肽表位的工程化细胞 |
| WO2025137580A1 (en) * | 2023-12-22 | 2025-06-26 | Antiger Therapeutics, Inc. | Class ii hla with inter-chain disulfide bond |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| JP2000516470A (ja) * | 1996-08-16 | 2000-12-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 可溶性一価および多価ｍｈｃクラスｉｉ融合タンパク質およびそれらの使用 |
| CA2302779C (en) * | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| WO1999060120A2 (en) * | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| RU2303264C2 (ru) * | 2001-02-19 | 2007-07-20 | Мерк Патент Гмбх | Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью |
| GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| US8377447B2 (en) * | 2003-09-05 | 2013-02-19 | Oregon Health & Science University | Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells |
| CA2638892A1 (en) | 2005-03-18 | 2006-09-28 | Oregon Health & Science University | Recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| JP5154564B2 (ja) * | 2006-12-01 | 2013-02-27 | カール・ツァイス・エスエムティー・ゲーエムベーハー | 像収差を低減するための交換可能で操作可能な補正構成を有する光学システム |
| ES2445152T3 (es) | 2007-08-20 | 2014-02-28 | Nextera As | Presentación en fagos de pVII |
-
2010
- 2010-02-18 GB GBGB1002730.8A patent/GB201002730D0/en not_active Ceased
-
2011
- 2011-02-18 AU AU2011217027A patent/AU2011217027B2/en active Active
- 2011-02-18 WO PCT/GB2011/050325 patent/WO2011101681A2/en not_active Ceased
- 2011-02-18 KR KR1020127024287A patent/KR101647176B1/ko active Active
- 2011-02-18 DK DK11730044.2T patent/DK2536746T3/en active
- 2011-02-18 HR HRP20160475TT patent/HRP20160475T1/hr unknown
- 2011-02-18 RS RS20160323A patent/RS54744B1/sr unknown
- 2011-02-18 PL PL11730044T patent/PL2536746T3/pl unknown
- 2011-02-18 ES ES11730044T patent/ES2572388T3/es active Active
- 2011-02-18 EP EP11730044.2A patent/EP2536746B1/en active Active
- 2011-02-18 RU RU2012138302/10A patent/RU2604813C2/ru active
- 2011-02-18 US US13/579,887 patent/US8828379B2/en active Active
- 2011-02-18 CA CA2789492A patent/CA2789492C/en active Active
- 2011-02-18 SI SI201130815A patent/SI2536746T1/sl unknown
- 2011-02-18 JP JP2012553409A patent/JP5537675B2/ja active Active
- 2011-02-18 CN CN201180011237.4A patent/CN102947330B/zh active Active
- 2011-02-18 HU HUE11730044A patent/HUE027952T2/en unknown
-
2014
- 2014-07-14 US US14/331,014 patent/US9056920B2/en active Active
-
2016
- 2016-05-11 CY CY20161100397T patent/CY1117697T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130009782A (ko) | 2013-01-23 |
| GB201002730D0 (en) | 2010-04-07 |
| WO2011101681A2 (en) | 2011-08-25 |
| JP5537675B2 (ja) | 2014-07-02 |
| AU2011217027B2 (en) | 2015-02-05 |
| CA2789492C (en) | 2017-04-18 |
| ES2572388T3 (es) | 2016-05-31 |
| KR101647176B1 (ko) | 2016-08-09 |
| US8828379B2 (en) | 2014-09-09 |
| PL2536746T3 (pl) | 2016-08-31 |
| SI2536746T1 (sl) | 2016-09-30 |
| RU2012138302A (ru) | 2014-03-27 |
| RU2604813C2 (ru) | 2016-12-10 |
| WO2011101681A3 (en) | 2011-12-08 |
| US20130171668A1 (en) | 2013-07-04 |
| US9056920B2 (en) | 2015-06-16 |
| JP2013519721A (ja) | 2013-05-30 |
| HUE027952T2 (en) | 2016-11-28 |
| EP2536746A2 (en) | 2012-12-26 |
| US20140349315A1 (en) | 2014-11-27 |
| HRP20160475T1 (hr) | 2016-06-03 |
| CN102947330B (zh) | 2015-09-16 |
| CY1117697T1 (el) | 2017-05-17 |
| CA2789492A1 (en) | 2011-08-25 |
| AU2011217027A1 (en) | 2012-09-06 |
| EP2536746B1 (en) | 2016-04-20 |
| CN102947330A (zh) | 2013-02-27 |
| DK2536746T3 (en) | 2016-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54744B1 (sr) | Rastvorljivi funkcionalni heterodimeri mhc klase ii stabilizovani disulfidnom vezom | |
| EP3850363B1 (en) | Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexes | |
| KR102499753B1 (ko) | Ｔ 세포 수용체 조작 | |
| US20240294601A1 (en) | Peptide deficient-mhc class i/chaperone compositions and methods | |
| KR20160085345A (ko) | 조작된 고-친화도의 인간 t 세포 수용체 | |
| US20080038282A1 (en) | Biotinylated MHC complexes and their uses | |
| JP2022522404A (ja) | Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 | |
| US20240262885A1 (en) | Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications | |
| WO2021224261A1 (en) | Soluble tors and fusions to anti-cd3 recognising kras g12d for the treatment of cancer | |
| Lybarger et al. | Tapasin enhances peptide-induced expression of H2-M3 molecules, but is not required for the retention of open conformers | |
| US20240076356A1 (en) | Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof | |
| Moro et al. | Generation of functional HLA-DR* 1101 tetramers receptive for loading with pathogen or tumour derived synthetic peptides | |
| HK1177939B (en) | Disulphide bond-stabilized functional soluble mhc class ii heterodimers | |
| Bandyopadhyay et al. | The relative energetic contributions of dominant P1 pocket versus hydrogen bonding interactions to peptide: class II stability: implications for the mechanism of DM function | |
| Sharma et al. | Refolding of HLA-B27 heavy chains in the absence of β2m yields stable high molecular weight (HMW) protein forms displaying native-like as well as non-native-like conformational features: Implications for autoimmune disease | |
| TW202208396A (zh) | Ｔ細胞調控性多聚體多肽和使用彼之方法 |